Scientist/Sr. Scientist, Cell Engineering (Process Development Group)

Posted 1 month ago

The Scientist/Sr. Scientist, Cell Engineering will be responsible for the establishment and execution of technical strategies to develop engineered mammalian-based producer and packaging cell lines used for the manufacturing of lentiviral vectors. This will include host selection, the design of gene editing and modification strategies, incorporation of transcriptional and epigenetic control approaches and subsequent technical evaluations to select lead candidates to support establishing CMC suitable cell lines for use in eventual GMP manufacturing of lentiviral vectors. The scientist will collaborate with process development scientists to incorporate the use of engineered cell lines in process development strategies

Principal Accountabilities:

• Lead the design and establishment of cell engineering strategies and capabilities to support the generation of packaging and producer cell lines

• Establish the incorporation of engineered cell lines in continuous manufacturing strategies for viral products

• Document all activities in accordance with AVROBIO’s data management policies and procedures

• Investigate opportunities to incorporate next generation technologies in gene editing and transcriptional regulation in the establishment of cell engineering and process control

• Participates in departmental goals and objective development

• Participate in the authoring of CMC sections of regulatory submissions

Qualifications:

• Ph.D in cell and molecular biology

• 5+ years of experience in cellular and molecular engineering of bacterial or mammalian cell lines, in particular in the development of packaging and producer cell lines for production of viral products


Click here for LinkedIn Easy Apply: Scientist/Sr. Scientist, Cell Engineering 

AVROBIO, Inc is an EEO employer

About AVRO
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its gene therapy candidate, AVR‑RD‑01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, Cystinosis and Pompe disease. AVROBIO’s lentiviral platform has broad potential for other rare and non-rare genetic diseases. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.

Apply Online